Who makes AD17137 topical treatment?

AD17137 topical treatment is developed by Assuta Hospital Systems.

What development phase is AD17137 topical treatment in?

AD17137 topical treatment is in Phase 2.

Last reviewed 2026-04-20 · How we verify

AD17137 topical treatment

Assuta Hospital Systems · Phase 2 active Small molecule Quality 3/100

At a glance

Generic name	AD17137 topical treatment
Sponsor	Assuta Hospital Systems
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of a Topical Treatment for Actinic Keratosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AD17137 topical treatment CI brief — competitive landscape report
AD17137 topical treatment updates RSS · CI watch RSS
Assuta Hospital Systems portfolio CI